Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the formation of noncaseating granulomas, multisystem organ involvement, and T-cell activation at the site of granulomatous inflammation with the release of various chemokines and cytokines. The prevalence of sarcoidosis is 3 – 25 cases per 100,000 population. The mainstay of sarcoidosis therapy is corticosteroids, immunosuppressants, and drugs that affect oxidative stress and tumor necrosis factor. The aim of the article was to introduce the latest procedures for the diagnosis and treatment of sarcoidosis of various localizations, agreed upon in the Russian Federation. The target audience for these clinical guidelines are general practitioners, internists, pulmonologists, phthisiologists, pathologists, radiologists, and rehabilitation physicians. Methods. Each recommendation statement for diagnostic and therapeutic measures is assessed using evidence levels ranging from 1 to 5 and a recommendation strength rating scale for categories A, B, and C. The clinical guidelines also contain commentary and explanations for these recommendations, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials. Conclusion. These clinical guidelines provide an overview of current knowledge on the etiology and pathogenesis, clinical manifestations, diagnosis, and treatment of sarcoidosis. These clinical guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2025.